288.30
+0.80%
Close of 9 Nov 2026, in ILA
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biolight Life Sciences
Its shares trade on Tel Aviv under the ticker BOLT.TA. It has been listed since 27 December 2005. In the fiscal year to 31 December 2024, it reported revenue of ILS 219,000 and a net loss of ILS 7.1m. At that date it held total assets of ILS 34.1m and shareholders' equity of ILS 26.9m.
BioLight Life Sciences Ltd. operates as an investment holding company, with interests in the area of research and development in the fields of medication and medical equipment. Its portfolio companies are IOptima Novel Glaucoma Treatment and Micromedic Technologies Ltd. The firm provides each of the subsidiaries with ongoing support, resources and expertise in science, regulation, business development, and intellectual property. IOptima Novel Glaucoma Treatment is engaged in the development, manufacturing and distribution of novel surgical treatments for glaucoma. Micromedic Technologies Ltd focuses, through its investee companies, on the development and commercialization of novel molecular biomarkers related to cancer, including early detection of disease, genetic risk and optimization of treatment modalities.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 27 Dec 2005
- Employees
- 18
- Website
- bio-light.co.il ↗
Leadership
Pay as last reported
- Mr. Israel MakovChairman of the Board, since 2011
- Mr. Yaacov MichlinChief Executive Officer
- Ms. Suzana Nahum-ZilberbergDeputy Chairman of the Board, since 2011
- Mr. Yifftach BielChief Financial Officer
- Ms. Karin GurevitzVice President, Group General Counsel, Company Secretary
- Dr. Ron NeumannChief Medical Officer
- Ms. Alla FelderDirector
- Ms. Rina ShafirDirector
- Mr. Jacob FaigenbaumIndependent Director
- Mr. Ron MayronIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biolight Life Sciences Ltd has a strong portfolio of innovative products in the biotechnology sector. Their research and development team is highly skilled and experienced, allowing them to develop cutting-edge solutions for various medical challenges. The company also has strong intellectual property rights, securing their competitive advantage in the market.
- Biolight Life Sciences Ltd has a widespread distribution network, enabling them to reach a large customer base both domestically and internationally. This network effectively markets their products and ensures a consistent revenue stream.
Weaknesses
- One of the potential weaknesses of Biolight Life Sciences Ltd is their heavy dependence on a few key products. If any of these products face certain challenges, such as regulatory issues or market saturation, the company's revenue may be significantly impacted.
- The company also faces stiff competition from established players and emerging startups in the biotechnology industry. This competition increases the pressure to continuously innovate and maintain a strong market presence.
Opportunities
- Biolight Life Sciences Ltd has significant opportunities to expand its market presence. With increasing global awareness and demand for personalized medicine, the company can capitalize on this trend by developing and commercializing genetic tests and personalized treatment options.
- The growing prevalence of chronic diseases presents another opportunity for Biolight Life Sciences Ltd. By focusing on developing therapies and diagnostic tools for these conditions, the company can tap into a large and potentially lucrative market.
Threats
- Regulatory challenges pose a significant threat to Biolight Life Sciences Ltd. Changes in government regulations, clinical trial requirements, or licensing restrictions can potentially disrupt their operations and delay product launches, negatively impacting their financial performance.
- Another threat is the rapid pace of technological advancements in the biotechnology industry. If Biolight Life Sciences Ltd fails to keep up with these advancements, they may become technologically obsolete, losing their competitive edge in the market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.